Skip to main content

Table 3 Characteristics of anti-MPO-positive vs anti-MPO-negative patients and anti-PR3-positive vs anti-PR3-negative patients

From: Significance of anti-neutrophil cytoplasmic antibodies in systemic sclerosis

  Anti-MPO negative
n = 1289
Anti-MPO positive
n = 13
p Anti-PR3 negative
n = 1284
Anti-PR3 positive
n = 18
p
Female 1115 (86.5%) 9 (69.2%) 0.089# 1112 (86.6%) 12 (66.7%) 0.014
Race
 Caucasian 1166 (90.5%) 12 (92.3%) 0.622# 1164 (90.7%) 14 (77.8%) 0.024#
 Asian 57 (4.4%) 1 (7.7%)   54 (4.2%) 4 (22.2%)  
 Aboriginal-Islander 15 (1.2%) 0 (0%)   15 (1.2%) 0 (0%)  
 Other 18 (1.4%) 0 (0%)   18 (1.4%) 0 (0%)  
Type of disease
 Limited 966 (74.9%) 8 (61.5%) 0.268 963 (75.0%) 11 (61.1%) 0.178
 Diffuse 323 (25.1%) 5 (38.5%)   321 (25.0%) 7 (38.9%)  
 Age of scleroderma onset, years 46.44 ± 14.27 42.23 ± 14.26 0.290 46.39 ± 14.29 46.86 ± 13.24 0.888
 Age at recruitment, years 57.76 ± 12.52 53.07 ± 14.02 0.180 57.71 ± 12.56 58.02 ± 11.17 0.916
 Disease duration at recruitment, years 8.31 (12.31) 13.07 (17.33) 0.924^ 8.29 (13.30) 11.31 (16.86) 0.934^
 Duration of follow-up, years 3.09 (4.50) 3.36 (3.48) 0.619^ 3.09 (4.50) 3.97 (3.83) 0.640^
 Ever smoked 633 (49.1%) 6 (46.2%) 0.832 634 (49.4%) 5 (27.8%) 0.069
Autoantibodies
 Anti-Scl-70 175 (13.6%) 5 (38.5%) 0.006 172 (13.4%) 8 (44.4%) < 0.001
 Anti-centromere 612 (47.6%) 1 (7.7%) 0.004# 608 (47.4%) 5 (27.8%) 0.092
 ANA 1211 (93.9%) 10 (76.9%) 0.036# 1205 (93.8%) 16 (88.9%) 0.285#
 Rheumatoid factor 335 (26.0%) 2 (15.4%) 0.532# 333 (25.9%) 4 (22.2%) 0.793#
 Anti-Ro 87 (6.7%) 0 (0.0%) > 0.999# 86 (6.7%) 1 (5.6%) > 0.999#
 Anti-La 20 (1.6%) 0 (0.0%) > 0.999# 20 (1.6%) 0 (0%) > 0.999#
 Anti-RNP 26 (2.0%) 0 (0.0%) > 0.999# 26 (2.0%) 0 (0%) > 0.999#
 Anti-dsDNA 41 (3.2%) 1 (7.7%) 0.385# 40 (3.1%) 2 (11.1%) 0.157#
 Anti-Sm 8 (0.6%) 0 (0.0%) > 0.999# 8 (0.6%) 0 (0.0%) > 0.999#
 Anti-Jo-1 7 (0.5%) 0 (0.0%) > 0.999# 7 (0.5%) 0 (0.0%) > 0.999#
 Anti-PM/Scl 15 (1.2%) 0 (0.0%) > 0.999# 15 (1.2%) 0 (0.0%) > 0.999#
 Anti phospholipid antibodies 302 (23.4%) 2 (15.4%) > 0.999# 397 (30.9%) 7 (38.9%) 0.105
 Anti-cardiolipin 259 (20.1%) 2 (15.4%) > 0.999# 234 (18.2%) 7 (38.9%) 0.600#
 Anti-beta 2 glycoprotein 93 (7.2%) 1 (7.7%) 0.539# 93 (7.2%) 1 (5.6%) 0.668#
 Lupus anticoagulant 34 (2.6%) 1 (7.7%) 0.226# 35 (2.7%) 0 (0.0%) > 0.999#
 Anti-RNA polymerase 113 (8.8%) 3 (23.1%) 0.136# 116 (9.0%) 0 (0.0%) 0.149#
Clinical characteristics and complications
 Pulmonary arterial hypertension 121 (9.4%) 1 (7.7%) > 0.999# 118 (9.2%) 4 (22.2%) 0.080#
 Interstitial lung disease 305 (23.7%) 5 (38.5%) 0.213 301 (23.4%) 9 (50.0%) 0.009
 Renal crisis 35 (2.7%) 0 (0.0%) > 0.999# 35 (2.7%) 0 (0.0%) > 0.999#
 Digital ulcers 639 (49.6%) 6 (46.2%) 0.806 635 (49.5%) 10 (55.6%) 0.607
 SIBO 37 (2.9%) 0 (0.0%) > 0.999# 37 (2.9%) 0 (0.0%) > 0.999#
 GAVE 112 (8.7%) 0 (0.0%) 0.616# 112 (8.7%) 0 (0.0%) 0.393#
 Oesophageal dysmotility 130 (10.1%) 1 (7.7%) > 0.999# 130 (10.1%) 1 (5.6%) > 0.999#
 Oesphageal stricture 143 (11.1%) 3 (23.1%) 0.171# 145 (11.3%) 1 (5.6%) 0.711#
 Synovitis 509 (39.5%) 7 (53.8%) 0.292 505 (39.3%) 11 (61.1%) 0.061
 Malignancy 250 (19.6%) 2 (15.4%) > 0.999# 249 (19.4%) 3 (16.7%) > 0.999#
 Hospitalised 484 (37.5%) 6 (46.2%) 0.524 481 (37.5%) 9 (50.0%) 0.276
 Deep vein thrombosis 89 (6.9%) 1 (7.7%) 0.608# 89 (6.9%) 1 (5.6%) > 0.999#
 Pulmonary embolus 44 (3.4%) 1 (7.7%) 0.368# 42 (3.3%) 3 (16.7%) 0.022#
 Overlap features with another connective tissue disease 74 (5.7%) 2 (15.4%) 0.173# 74 (5.8%) 2 (11.1%) 0.283#
 Overlap syndrome with rheumatoid arthritis 25 (1.9%) 2 (15.4%) 0.028# 25 (1.9%) 2 (11.1%) 0.052#
 Overlap syndrome with polymyositis 13 (1.0%) 0 (0.0%) > 0.999# 13 (1.0%) 0 (0.0%) > 0.999#
 Overlap syndrome with Sjogren’s 24 (1.9%) 0 (0.0%) > 0.999# 24 (1.9%) 0 (0.0%) > 0.999#
 Overlap syndrome with SLE 12 (0.9%) 0 (0.0%) > 0.999# 12 (0.9%) 0 (0.0%) > 0.999#
 Overlap syndrome with dermatomyositis 1 (0.1%) 0 (0.0%) > 0.999# 1 (0.1%) 0 (0.0%) > 0.999#
Treatments
 Prednisolone 570 (44.2%) 9 (69.2%) 0.093# 568 (44.2%) 11 (61.1%) 0.153
 Azathioprine 101 (7.8%) 3 (23.1%) 0.079# 101 (7.9%) 3 (16.7%) 0.169#
 Mycophenolate 100 (7.8%) 2 (15.4%) 0.271# 98 (7.6%) 4 (22.2%) 0.046#
 Cyclophosphamide 113 (8.8%) 4 (30.8%) 0.023# 113 (8.8%) 4 (22.2%) 0.071#
 Calcium channel antagonist 836 (64.9%) 10 (76.9%) 0.364# 833 (64.9%) 13 (72.2%) 0.516
 Topical vasodilator 103 (8.0%) 2 (15.4%) 0.283# 103 (8.0%) 2 (11.1%) 0.651#
 Iloprost 160 (12.4%) 1 (7.7%) > 0.999# 159 (12.4%) 2 (11.1%) > 0.999#
 Operation for peripheral vascular disease 14 (1.1%) 0 (0.0%) > 0.999# 14 (1.1%) 0 (0%) > 0.999#
 Penicillamine 105 (8.1%) 3 (23.1%) 0.086# 105 (8.2%) 3 (16.7%) 0.183#
 Rituximab 10 (0.8%) 1 (7.7%) 0.105# 10 (0.8%) 1 (5.6%) 0.142#
 Abatacept 1 (0.1%) 0 (0.0%) > 0.999# 1 (0.1%) 0 (0%) > 0.999#
 TNF alpha inhibitor 11 (0.9%) 0 (0.0%) > 0.999# 11 (0.9%) 0 (0%) > 0.999#
 Tocilizumab 5 (0.4%) 0 (0.0%) > 0.999 5 (0.4%) 0 (0%) > 0.999
 Biologics ever 25 (1.9%) 1 (7.7%) 0.232# 25 (1.5%) 1 (5.6%) 0.306#
  1. Values are given as number (%), mean ± SD or median (IQR)
  2. Abbreviations: ANA anti nuclear antibodies, ANCA anti-neutrophil cytoplasmic antibodies, anti-phospholipid antibodies: any one or combination of anti-cardiolipin, anti-beta-2-glycoprotein and lupus anticoagulant, anti-dsDNA anti-double stranded deoxyribonucleic acid, anti-RNP ribonucleoprotein, SIBO small intestinal bacterial overgrowth, SLE systemic lupus erythematosus, anti-Sm anti-Smith
  3. ^Rank sum test
  4. #Fisher’s exact test